Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair
Androgen-deprivation therapy was shown to improve treatment outcome of external beam radiation therapy (EBRT) for locally advanced prostate cancer (PCa). DNA damage response (DDR) was suggested to play a role in the underlying mechanism, but conflicting results were reported. This study aims to reve...
Main Authors: | Wenhao Zhang, Chen-Yi Liao, Hajar Chtatou, Luca Incrocci, Dik C. van Gent, Wytske M. van Weerden, Julie Nonnekens |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1593 |
Similar Items
-
Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of <i>Pten</i>-Deficient Prostate Cancer
by: Marco A. De Velasco, et al.
Published: (2021-08-01) -
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01) -
USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer
by: Arishya Sharma, et al.
Published: (2020-09-01) -
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
by: Gul A, et al.
Published: (2019-08-01) -
Characterization of APLF in Non-homologous End-joining
by: Shirodkar, Purnata V.
Published: (2011)